Navigation Links
Lilly's Investigational GLP-1 Receptor Agonist, Dulaglutide, Showed Superior Glycemic Control Versus Comparators in Patients with Type 2 Diabetes
Date:6/22/2013

provides answers—through medicines and information—for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. P-LLY

This press release contains forward-looking statements about dulaglutide that are based on Lilly's current expectations. Actual results could differ materially from these expectations. There are significant risks and uncertainties in the process of drug development and commercialization. There can be no guarantee that future study results and patient experience will be consistent with the study findings to date. There can also be no guarantee that dulaglutide will be submitted to regulatory authorities in 2013, that it will receive the necessary clinical and manufacturing regulatory approvals, or that it will prove to be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, please see the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Except as required by law, the company undertakes no duty to update forward-looking statements.

Refer to: Candace Johnson, +1-317-755-9143, johnson_candace_a@lilly.com

[1]Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide vs placebo and exenatide in type 2 diabetes (AWARD-1). Abstract 66-OR. Presented at: American Diabetes Association (ADA) 73rd Scientific Sessions; June 21-25, 2013; Chicago, IL.

[2]Umpierrez GE, Manghi FP, Povedano ST, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide vs metformin in type 2 diabetes (AWARD-3). Abstract 69-OR. Presented at: American Diabetes Association (ADA) 73rd Scientific Sessions; June 21-25, 2013; Chicago, IL.

[3]Nauc
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
2. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
3. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
4. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
5. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
6. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
7. Can a genetic variation in the vitamin D receptor protect against osteoporosis?
8. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
9. Receptos Co-Publishes Highest Resolution G-Protein Coupled Receptor Structure to Date in Science
10. Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science
11. Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AudioNotch is the internet's leading provider of ... of tinnitus. Patients listen to sound therapy that is ... of weeks to months, their tinnitus volume decreases. , AudioNotch ... Music and Notched White Noise. Now, AudioNotch is pleased to ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... owners drew up their lists of New Year,s resolutions for 2014, ... my furry companion." Nowadays there are pet salons, dog and cat ... the little canine or feline darlings along wherever mommy or daddy ... toys at the pet store. But anyone who has ever lived ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... -- Spectrum Equity Investors of Boston will become the ... national provider of technology to mortgage lenders. , , ... an $84 million recapitalization of Mortgagebot. , ,Following the ... join Mortgagebot's board of directors. Terms of the transaction ...
... -- Metavante Corp., the financial technology subsidiary of Marshall ... of Nashville, Tenn., The company will continue to operate ... subsidiary of Metavante , with existing management continuing ... the transaction were not disclosed. , ,LINK2GOV provides ...
... The WiCell Research Institute's announcement Monday that it has ... to create the nation's first National Stem Cell Bank ... and innovative approach to the new field of research. ... opposition to embryonic stem cell research, the path forward ...
Cached Biology Technology:Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot 2Metavante acquiring LINK2Gov 2WiCell to host new national stem cell bank 2WiCell to host new national stem cell bank 3WiCell to host new national stem cell bank 4
(Date:7/9/2014)... considered a healthy source of protein, that,s not why the ... be presented at Tops Club Inc.,s annual International Recognition Days ... are 20-something women who want dishes that are quick, easy ... "They basically seem to care less about any health benefits ... it to look good and because it,s quick to cook ...
(Date:7/9/2014)... , an associate professor of plant pathology and ... been awarded the 2014 Alexopoulos Prize by ... to advancing the science of mycology the study ... yeasts, lichens, plant pathogens, and medically important fungi. , ... outstanding early-career mycologist. Stajich received the award last month ...
(Date:7/9/2014)... 2014) Emerging fungal pathogens pose a greater ... causing population declines of amphibians, bats, corals, bees ... South Florida published in the prestigious journal ... or immunological resistance to a deadly chytrid fungus ... "Acquired resistance is important because it is the ...
Breaking Biology News(10 mins):UC Riverside plant pathologist receives national recognition 2USF study: Amphibians can acquire resistance to deadly fungus 2
... AWRE ), a leading supplier of broadband technology and biometrics ... 30, 2010.   Revenues for the third quarter of ... million in the same quarter last year. Net income for the ... These results compared to a net loss of $1.1 million, or ...
... BOSTON The discovery that a protein called Rictor plays ... AKT oncogene could provide scientists with a new molecular target ... September 2010 issue of the journal Molecular Cell , ... Medical Center (BIDMC). The oncogenic cousin, known as ...
... Nanomedicine Center for Nucleoprotein Machines has received an award ... its renewal by the National Institutes of Health (NIH). ... of a clinically viable gene correction technology for single-gene ... disease. Sickle cell disease is a genetic condition ...
Cached Biology News:Aware, Inc. Reports Third Quarter 2010 Financial Results 2Aware, Inc. Reports Third Quarter 2010 Financial Results 3Aware, Inc. Reports Third Quarter 2010 Financial Results 4Aware, Inc. Reports Third Quarter 2010 Financial Results 5Rictor protein offers scientists a new molecular target for cancer therapies 2NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 2NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 3NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 4
... 14 3C protease from human rhinovirus (HRV ... Novagen brand line of restriction grade proteases. ... recombinant 6XHis-fusion protein, which recognizes the same ... The small, 22 KDa size of the ...
...
... a tradition of progressive centrifuge design and ... The Centra-CL3 and Centra-CL3R (refrigerated) general purpose ... Quality Control Over Sample Preparation , ... up to 99 protocols and has speed ...
PP2B-Abeta (C-20)...
Biology Products: